Oncology - Medicine.net

Old drugs offer new ways of treating bowel cancer

byUniversity of AucklandCredit: CC0 Public DomainOld medicines, combined in new ways, are showing promise for treating bowel cancer, a group of University of Auckland researchers has found.&quot

Updated on: December 26,2023

Old drugs offer new ways of treating bowel cancer

byUniversity of AucklandCredit: CC0 Public DomainOld medicines, combined in new ways, are showing promise for treating bowel cancer, a group of University of Auckland researchers has found.&quot

Updated on:December 26,2023

Researchers identify path to prevent cognitive decline after radiation

by Kelsie Smith Hayduk,University of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainResearchers at the Del Monte Institute for Neuroscience at the University of Rochester find that mic

Updated on: January 09,2024

Researchers identify path to prevent cognitive decline after radiation

by Kelsie Smith Hayduk,University of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainResearchers at the Del Monte Institute for Neuroscience at the University of Rochester find that mic

Updated on:January 09,2024

Study shows a computerized decision support system reduces high-risk drug combinations in ICU patients

by Amsterdam University Medical CenterCredit: Pixabay/CC0 Public DomainA multicenter study led by Amsterdam UMC and conducted in nine Dutch Intensive Care Units (ICUs) has shown that tailoring a compu

Updated on: May 16,2024

Study shows a computerized decision support system reduces high-risk drug combinations in ICU patients

by Amsterdam University Medical CenterCredit: Pixabay/CC0 Public DomainA multicenter study led by Amsterdam UMC and conducted in nine Dutch Intensive Care Units (ICUs) has shown that tailoring a compu

Updated on:May 16,2024

Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer

byAmerican Association for Cancer ResearchNeoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to m

Updated on: December 22,2023

Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer

byAmerican Association for Cancer ResearchNeoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to m

Updated on:December 22,2023

Blood-clotting protein and blood platelets promote immune evasion, cancer progression

byOhio State University Medical CenterCredit: CC0 Public DomainA new study led by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard

Updated on: December 20,2023

Blood-clotting protein and blood platelets promote immune evasion, cancer progression

byOhio State University Medical CenterCredit: CC0 Public DomainA new study led by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard

Updated on:December 20,2023

Drugs for treating breast cancer in women are effective and well tolerated in men

byEuropean Society for Medical OncologyThere is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the la

Updated on: December 18,2023

Drugs for treating breast cancer in women are effective and well tolerated in men

byEuropean Society for Medical OncologyThere is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the la

Updated on:December 18,2023

Response to neoadjuvant chemo for breast cancer varies by sex

Both proportions and odds of pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) are numerically lower in men with breast cancer (BC) versus women with BC for each tumor subtype, acco

Updated on: December 20,2023

Response to neoadjuvant chemo for breast cancer varies by sex

Both proportions and odds of pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) are numerically lower in men with breast cancer (BC) versus women with BC for each tumor subtype, acco

Updated on:December 20,2023

World-first treatment with 'acoustic cluster therapy' to improve chemotherapy delivery

byInstitute of Cancer ResearchCredit: CC0 Public DomainThe first patient has been treated with an innovative new technology that uses microscopic clusters of bubbles and liquid droplets to enhan

Updated on: December 23,2023

World-first treatment with 'acoustic cluster therapy' to improve chemotherapy delivery

byInstitute of Cancer ResearchCredit: CC0 Public DomainThe first patient has been treated with an innovative new technology that uses microscopic clusters of bubbles and liquid droplets to enhan

Updated on:December 23,2023

Detailed diagnosis boosts child cancer survival

byCancer Research UK| News6 March 2009More accurate disease classification now means some young children with neuroblastoma will have less intensive treatment with better survival, accordi

Updated on: December 19,2023

Detailed diagnosis boosts child cancer survival

byCancer Research UK| News6 March 2009More accurate disease classification now means some young children with neuroblastoma will have less intensive treatment with better survival, accordi

Updated on:December 19,2023

Sam's Club charcuterie meats recalled due to salmonella risk

by Ernie Mundell, U.S. Centers for Disease Control and PreventionA salmonella outbreak that's already sickened 24 people is triggering the recall of charcuterie meats sent to Sam's Club distri

Updated on: May 26,2024

Sam's Club charcuterie meats recalled due to salmonella risk

by Ernie Mundell, U.S. Centers for Disease Control and PreventionA salmonella outbreak that's already sickened 24 people is triggering the recall of charcuterie meats sent to Sam's Club distri

Updated on:May 26,2024

Treatment of aggressive breast cancer improved by immunotherapy-chemotherapy combination

byUniversity of Pittsburgh Schools of the Health SciencesLeisha Emens, M.D., Ph.D., co-leader of the UPMC Hillman Cancer Immunology and Immunotherapy Program. Credit: UPMCPatients with an aggres